Brainstorm Cell Therapeutics (BCLI)
(Real Time Quote from BATS)
$0.58 USD
+0.01 (1.40%)
Updated May 23, 2024 02:24 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Brainstorm Cell Therapeutics Inc. [BCLI]
Reports for Purchase
Showing records 21 - 40 ( 66 total )
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverage of Brainstorm Cell Therapeutics, Inc. due to the departure from the firm of the covering analyst.
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEDE K
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are Initiating Coverage at BUY rating
Provider: DAWSON JAMES SECURITIES, INC.
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The ALS Pivotal Trial Could Complete Enrollment by the Middle of Next Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
82 Patients Enrolled; 110 Anticipated by January 2019 With 90 Remaining
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Funded Through Phase 3, Enrollment Update Expected in August
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
"Right to Try" is Complicated; Especially Without Funding
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Need Is Desperate as ALS Patients Through "Right To Try" Request Access to NurOwn Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J